IFNB1 and myeloid sarcoma: At present, no additional benefit of a higher GA dose has been found, and the effect of the drug on the recurrence rate of MS after 2 yr of treatment is similar to that of IFN-β (Comi et al., 2011; La Mantia et al., 2015; van Dijkman et al., 2018).